Introduction
Primary islet dysfunction and chronic rejection are the major reasons why islet transplantation has not yet achieved its initial promise. [1] [2] [3] Primary islet dysfunction is the consequence of overlapping pathways. First, the isolation procedure physically promotes trauma, resulting in the nonspecific increase of inflammatory cytokines and free radicals. 4, 5 Despite the best efforts to remove cytokines or the cells that secrete them, like islet-resident dendritic cells or macrophages during or post-isolation, the small but biologically relevant cytokine amounts carried over into the islet preparation are capable of recruiting antigen-presenting cells (APC), like macrophages and host dendritic cells, to the site of engraftment. 4, 5 The second reason why islets are still not an accepted clinical regimen for insulin replacement is their allogeneic nature, which provokes acute and chronic allograft rejection. It appears that cytokine carryover inside the transplant and the immune cells of the host that can be mobilized by these cytokines are primary determinants of transplant survival. 4, [6] [7] [8] [9] Modalities to scavenge these cytokines locally would be one means to prevent or suppress inflammation, ultimately prolonging islet graft survival.
Among the cytokines examined, those secreted by macrophages (the earliest infiltrating cells into grafts) are key to chronic rejection. [9] [10] [11] [12] [13] Tumor necrosis factor alpha (TNFa) is a primary determinant in stimulating the immune system, with direct effects on transplant survival as well as indirect effects via other cytokines (like interleukin-1b) acting on the graft tissue or in promoting the activity of downstream infiltrating cells like T cells. [14] [15] [16] [17] [18] A large body of evidence strongly supports a key and dominant role for TNFa in allograft rejection and discussion of this evidence is beyond the objectives of this manuscript. The reader is urged to consult the excellent review by Azzawi and Hasleton. models. [20] [21] [22] That TNFa was linked to diabetes developmentally was first suggested in studies showing TNFa gene expression in inflamed islets. 23 Compelling support for an important role of TNFa in diabetes was provided by the demonstration that neutralizing anti-TNFa antibodies protected against diabetes in the nonobese diabetic (NOD) mouse, whereas recombinant cytokine exacerbated the incidence and severity. 24 A series of further studies have shown that transgenic mice, including the NOD mouse, expressing soluble type 1 TNF receptors secreted from b cells, can escape insulitis and diabetes. [25] [26] [27] These soluble receptors act as decoys that prevent the interaction of TNFa with its cell-bound receptor. Similar observations have been made in a rabbit model of rheumatoid arthritis, where the degree of inflammation of arthritic joints was shown to be significantly reduced where soluble receptors were locally produced following adenoviral gene transfer (reviewed in Robbins 28 and Chernajovsky
29
). With these observations in mind, we proposed that ex vivo gene transfer of soluble type 1 TNF receptor decoys could confer a state of cytoprotection to islets that, when transplanted, could resist the effects of TNFa and prolong islet allograft survival. Herein we demonstrate that adenoviral gene transfer of a soluble type 1 TNF receptor decoy (Ad-TNFR-Ig) into human islets in vitro can prevent cytokine-mediated b-cell dysfunction and apoptosis and can facilitate allogeneic islet transplantation concomitant with normalization of glycemia in recipient diabetic mice. These data further support the feasibility of gene transfer of immunoregulators to intact islets to promote the integrity and survival of b cells and further strengthen the rationale to use gene-engineered islets as a potential solution to correct the chronic hyperglycemia of diabetes.
Results

Ad-TNFR-Ig gene transfer to islets results in high TNFR-Ig protein secretion
Adenoviral gene transfer to human and murine islets is very efficient. [30] [31] [32] [33] We have demonstrated that infection of human islets with recombinant, replicationdefective adenoviruses deleted for E1 and E3 results in very high levels of transgene expression, without affecting the ability of the b cells to respond normally to a glucose challenge. [33] [34] [35] Groups of 200-300 islets were routinely infected within 48-72 h following islet isolation from cadaveric donor pancreata. Islets were infected with Ad-TNFR-Ig as well as Ad-eGFP at 1 Â 10 6 plaque forming unit (PFU), in a minimal volume of serum-free medium. TNFR-Ig protein was detected in the culture supernatant by commercially available ELISA. In Ad-TNFR-Ig-transduced islet culture supernatants, TNFR-Ig was detected at 652728 pg/ml (n ¼ 5) 3 days following infection; however, no protein was detectable in the supernatants of untransduced islets. To further confirm these data, we performed Western blotting of islet lysates from intact islets transduced with Ad-TNFR-Ig. Figure 1a demonstrates that the transgene was indeed produced specifically from transduced islets and its level of expression was dependent on the multiplicity of infection (MOI) of the vector (Figure 1a , lanes 5 and 6).
Prevention of cytokine (IL-1b and TNFa)-induced suppression of glucose-stimulated insulin release by islets expressing TNFR-Ig in vitro
To determine if endogenously produced, islet-secreted TNFR-Ig was able to prevent or suppress the deleterious effects of cytokines (TNFa/IL-1b combination) on islet b-cell function, intact transduced islets were treated with 75-100 U of TNFa and 50 U of recombinant IL-1b. This amount of each cytokine in combination has been shown to consistently impair glucose-induced insulin production in uninfected islets, as well as in those infected with the Ad-LacZ control virus. 7, 8, 17, 18, [33] [34] [35] [36] [37] [38] [39] In dynamic glucose perifusion studies, we observed that TNFa addition for 18-24 h was sufficient to significantly reduce islet sensitivity to glucose (assessed by insulin production). The combination of TNFa and IL-1b almost completely suppressed insulin production ( Figure 1b and Table 1 ). Ad-TNFR-Ig-transduced islets, however, exhibited marked resilience to the effects of the cytokine combination and the perifusion response, as measured by insulin output, which was comparable to that of untransduced, untreated islets, although the magnitude of insulin released was not as high as that observed in untransduced, untreated islet supernatants. Viral transduction alone had no effects on the perifusion dynamics ( Figure 1b) .
Human islets infected with Ad-TNFR-Ig exhibit resistance to cytokine (IL-1b/TNFa)-stimulated apoptosis activation in vitro
To examine the effect of Ad-TNFR-Ig transduction of human islets to confer cytoprotection in the presence of proapoptotic cytokines, we performed FACS analysis on single cells from intact islets for Annexin V levels and propidium iodide uptake. As shown in Figure 2 , Annexin V/propidium iodide levels were dramatically reduced in single cells from intact islets infected with Ad-sTNFR-Ig in the presence of TNFa/IL-1b, compared with Annexin V levels in untransduced islets exposed to the cytokine combination. TNFa alone did promote an increase in apoptosis activation, but not as significant as that achieved by TNFa/IL-1b combination. The absence of any cytoprotective effect by Ad-eGFP rules out the possibility that the vector nonspecifically promotes resistance to the cytokines (Figure 2 ).
Prolongation of survival of TNFR-Ig-expressing islet allografts in immunocompetent mouse recipients
To confirm the cytoprotective effect of Ad-TNFR-Ig transduction in culture, we transplanted infected intact islets from mice into allogeneic diabetic recipients. In all, 300-400 islets transduced in culture with 1 Â 10 6 PFU Ad-TNFR-Ig virus were transplanted underneath the kidney capsule of each mouse in the indicated cohort ( Figure  3a) . Individual mice of a parallel cohort received an equal number of untransduced islets. Prior to the transplantation, each islet recipient in both cohorts was rendered diabetic by a single injection of streptozotocin. Diabetes (blood glucose 4320 mg/dl) consistently occurs by 24-30 h following streptozotocin injection in our studies (streptozotocin injection of 180 mg/kg body weight). Recipients of Ad-TNFR-Ig-transduced allogeneic islets remained diabetes-free for a significantly longer time than recipients of untransduced islets (Figure Adenoviral Table 2 ). In the diabetes-free recipients, fasting glycemia remained in the normal range (o250 mg/dl in tail vein blood) until the time of diabetes onset ( Figure  3b ). Although we have not included the survival of recipients of allogeneic islets transduced with control vector (Ad-eGFP or Ad-LacZ), our previous observations indicate that the mean survival time is 27712 days, with a median of 30 days on average. 40, 41 Clearly, our recipients of Ad-TNFR-Ig-transduced islets exhibit significantly longer survival in the diabetes-free state. We also examined the histology of the graft-bearing kidneys in diabetes-free recipients and confirmed insulin 6 PFU of Ad-TNFR-Ig and exposed to 75-100 U TNFa/ 50 U of IL-1b for a period between 18 and 24 h. Islets were then subjected to a dynamic 60-min glucose perifusion assay. Insulin was measured in the supernatant by ELISA and insulin output per islet culture was corrected by DNA content in the cluster using the fluorescent CyQuant reagent. At the top of the graph, we show the major time points of the perifusion. The x-axis represents the glucose concentration in the medium during the assay for the given time intervals (illustrated at the top of the graph) and the y-axis represents the insulin secreted at specific time points corrected by the DNA content of the insulin-secreting islets. These perifusion data are representative of three independently performed assays using islets from different cadaveric donors.
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J Machen et al positivity within the islet grafts (data not shown). Despite the absence of any evidence of immune infiltration, the amount of insulin positivity was significantly lower compared with the amount observed in grafts of syngeneic islets (data not shown). We are currently determining the reasons for this loss of insulin mass in the absence of any immune cell infiltration.
Discussion
The processes that lead to autoimmune diabetes mellitus include an as-yet-undefined trigger, perhaps islet-intrinsic, that activates islet-resident APC to acquire antigens expressed by b cells. It is thought that antigen acquisition is consequent to b-cell apoptosis. Once activated, the APC are able to migrate to the peripheral lymphoid organs, where they can activate autoreactive naïve T lymphocytes that have escaped thymic or peripheral negative selection. 42, 43 Pro-inflammatory cytokines such as TNFa and IL-1b play important roles in this process. 7, 44 In addition to the natural progression of islet inflammation, these cytokines are highly relevant for primary transplant dysfunction, especially of islets, as Insulin secretion into the supernatant of islets expressing TNFR-Ig with or without exposure to IL-1b/TNFa was determined at multiple timepoints over a 1-h perifusion assay as illustrated in Figure 1b . The immunoreactive insulin levels at every 10 min of the assay (by ELISA) corrected by islet DNA content are shown. The differences in magnitude of secreted insulin levels shown are representative of those observed in three other independent perifusion assays using islets from different cadaveric donors. a Indicates significantly higher insulin production from islets expressing TNFR-Ig exposed to the combination of IL-1b/TNFa cocktail compared to that from untransduced islets. The number of days of normoglycemia (blood glucose o250 mg/dl) in allogeneic islet recipients illustrated in Figure 3a are shown. Po0.0001 between Ad-TNFR-Ig-transduced islet recipients versus control islet (untransduced) recipients; Kaplan-Meier log-rank test. a Note that only diabetic mice from the Ad-TNFR-Ig islet transplant cohort have been included for analysis to determine the median and mean survival time.
Adenoviral TNFR-Ig gene transfer to islets J Machen et al well as the initiation of chronic transplant rejection. 45, 46 Local blockade of these cytokines could confer a shield of immune cover to the transplant, thereby prolonging the life and function of the transplant. TNFa and IL-1b are released by macrophages and, very likely, dendritic cells in response to a variety of anomalous changes in a given tissue. [47] [48] [49] [50] 17 The importance of these two cytokines by islet-resident APC in the onset of autoimmune diabetes has been suggested in several related studies. Depletion of macrophages in BB rats and in cyclophosphamidetreated NOD mice by silica particles has been shown to prevent diabetes. [51] [52] [53] [54] [55] In rodents, islet-resident macrophages are important for the initiation of b-cell dysfunction and produce TNFa, resulting in the induction of nitric oxide (NO) production by upregulation of the inducible nitric oxide synthase enzyme (iNOS). [56] [57] [58] [59] Production of these cytokines in transplanted tissue is a key determinant of chronic rejection. [60] [61] [62] In our studies, the addition of TNFa alone to human cultured islets was not capable of inducing significant apoptosis activation above that observed in untreated islet cultures. This confirms previous data demonstrating the requirement of at least IL-1b to activate apoptotic pathways. 7, 44, 63 TNFa, signalling through TNF receptor 1-associated death domain protein (TRADD), may be effective in inducing apoptosis in certain cell types, but islet cells, especially b cells, may be refractory to TRADD signalling and may require the interleukin-1 receptorassociated kinase (IRAK)-mediated pathway to directly activate apoptosis. We and others have shown that IL-1b is sufficient to induce caspase-3 activity as well as other markers of apoptosis activation in beta cells, without the need for additional cytokines. [33] [34] [35] 64 Nevertheless, the highest levels of apoptosis are achieved by combination cytokine provision, 7, 44, 63 suggesting that TNFa could sensitize cells to the effects of IL-1b or could prime these cells for IRAK-mediated signaling. 21, 22, [65] [66] [67] [68] [69] Although TNFR-Ig confers protection to human islets from TNFa effects, it was not effective in completely preventing apoptosis activation in culture, as measured by Annexin V staining in FACS analysis. This is not unexpected in the light of the preceding discussion. What was interesting was that allogeneic islet transplants expressing TNFR-Ig were functional over a significant time period, conferring normoglycemia to the recipient mice. These observations are in support, albeit indirect, that TNFa could lie at the apex of multiple intracellular signaling pathways to activate apoptosis, one very likely being by the direct activation of IL-1b expression and secretion by recipient APC like macrophages. Suppression of TNFa availability by a decoy receptor approach could inhibit the activation of TNFa-dependent gene expression and effector function of allograft earlyinfiltrating cells, but, with time, other infiltrating cells would induce islet dysfunction through other, TNFainsensitive and independent pathways. Indeed, this is supported by the eventual return to hyperglycemia by 53 days post-transplantation in some of the recipients of Ad-TNFR-Ig-transduced islets. This suggests that interference of the TNFa signaling pathway alone is not sufficient to achieve indefinite prolongation of allograft survival. We are in the process of transducing allogeneic islets with combinations of inhibitors of multiple proapoptotic pathways in efforts to achieve indefinite survival.
Many studies have addressed the relevance of viral vector immunogenicity in transplant models and the nature of the adenoviral backbone is well known to promote nonspecific immune activation and nonspecific biologic responses. [70] [71] [72] [73] Histologic evaluation of the kidney capsule underneath which we transplanted the Ad-TNFR-Ig-transduced islets demonstrated insulin staining (albeit weak and sparse), without evidence of immune infiltration (data not shown). Although we were unable to detect transgene expression by immunohistochemistry, we believe that there was a non-T-cell (very likely macrophage) infiltration at some point prior to the pathological investigation of these mice, which induced allogeneic b-cell impairment and perhaps loss. Whether a potential macrophage activity was a response to viral vector-encoded proteins possibly secreted by, or expressed on the islet cells, or to islet alloantigens is not known. It is well known that macrophages are among the first immune cells to infiltrate allografts and, certainly, islet allografts. 9 We additionally observed a decrease in insulin output in islets transduced with Ad-TNFR-Ig alone. It is not clear if this decrease is mechanistically linked to the expression of the TNFR-Ig transgene or to proteins expressed from the viral backbone, although we have observed similar reductions in insulin production using empty vectors (unpublished observations). How the viral backbone might affect the glucose response and insulinsecretory mechanisms in beta cells is not known, but could involve multiple pathways at the time of viral entrance into the cell via endosomes (which interact with the secretory pathway in late endosomes), or by appropriating transcription factors that normally promote the expression of genes involved in glucose sensing and insulin secretion/processing.
Our data support the feasibility of using secreted decoys and inhibitors of proapoptotic proteins to prolong islet allograft survival. We believe that our decoy approach neutralizes the TNFa secreted by T cells and possibly macrophages, and raises the threshold for b-cell dysfunction in glucose responsiveness. Nonetheless, other cytokines like IL-1b may be more directly relevant in ultimately directing an allogeneic response in vivo. Our data highlight the evidence that more than one proapoptotic pathway may need to be targeted to confer persistent protection of islet transplants in allogeneic recipients. With the availability of vectors capable of multicistronic expression, this concept can be readily tested as one means of facilitating islet transplantation as a potential therapy for autoimmune diabetes.
Materials and methods
Generation of recombinant adenoviruses
Viral vectors derive from replication-deficient type 5 adenovirus backbone deficient in E1 and E3 loci. 74, 75 The transgenes (eGFP or TNFR-Ig) were cloned into the E1 region, with expression driven by the cytomegalovirus promoter. Ad-TNFR-Ig encodes a fusion protein consisting of the extracellular domain of the human 55-kDa TNF receptor and the CH2-CH3 domains of a mouse IgG1 heavy chain.
75,76
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Isolation, culture and transplantation of islets
Human islets were obtained from the Islet Isolation Core of the Diabetes Institute of the University of Pittsburgh. Pancreata were obtained from at least five cadaveric donors of different ages and sex, and subjected to digestion, isolation and purification as described. 77, 78 For each experiment, islets from all donors were used. The purity of islets was usually greater than 80% (mantled islets). Viability of the cultured islets was routinely greater than 85%, as assessed by vital dye exclusion, insulin staining and morphology. Immediately after isolation, human islets were maintained in CMRL 1066 with 10% fetal calf serum (Invitrogen-Gibco Life Sciences, Gaithersburg, MD, USA) between 24 and 28 h before use. Mouse islets were isolated from Balb/c mice (8-10 weeks of age) as described in Bertera et al. 79, 80 Briefly, immediately after euthanasia by cervical dislocation, the pancreas was exposed and the bile duct clamped at the point where it enters the duodenum. Using a 27-gauge needle, 3 ml of a 1.75 mg/ml collagenase type V in cold Hanks buffered salt solution (HBSS) was injected into the bile duct. Upon complete inflation, the pancreas was removed from the surrounding tissue. The pancreas was digested in collagenase and the islets were obtained following Ficoll-400 density centrifugation and hand picking. 81 Hand-picked islets (on average islets of 150 mm diameter were selected) were maintained in RPMI 1640 medium with 10% fetal calf serum until use.
Groups of 300-400 Balb/c islets (infected or control) were used for transplantation into genetically discordant C57BL/6 mice (Balb/c H2 d versus C57BL/6 H2 b ; 8-10 weeks of age). Transduced islets (see below) were washed and transplanted underneath the kidney capsule of C57BL/6 recipients previously rendered diabetic by intraperitoneal streptozotocin injection (180-250 mg/kg body weight). Diabetes routinely ensues by 30 h following the injection (blood glucose 4320 mg/dl). Transplantation was performed immediately following confirmation of hyperglycemia in the streptozotocintreated mice. Briefly, the transplantation procedure involves initially aspirating groups of 300-400 islets into PE50 tubing. The islets are then gently centrifuged within the tubing, which is subsequently connected to a Hamilton syringe. Under anesthesia with Avertin (0.37-0.42 mg/g body weight), the left kidney of recipient mice was exposed following lumbar incision under sterile conditions in a laminar flow hood. A capsulotomy was performed in the lower kidney pole and the tubing with the islets was inserted beneath the kidney capsule. The tubing was gently manipulated to the upper pole and the islets gently injected under the kidney capsule. The kidney was replaced in the abdominal cavity and the body wall sutured followed by skin closure with small wound clips. The mice were kept warm and under observation, until they recovered from the anesthesia. In streptozotocin-treated mice, the onset of hyperglycemia (tail vein blood glucose 4300 mg/dl ascertained by electronic glucometer) is usually indicative of significant destruction of b cells, and therefore of diabetes and transplant destruction. Transplant destruction was defined as the time when two consecutive readings of 4300 mg/dl blood glucose were observed. A subset of mice were euthanized and nephrectomy was performed for immunohistological and cytological evaluation, which included insulin content (anti-insulin antibody, DAKOCytomation, Carpinteria, CA, USA).
Gene transfer of human TNFR-Ig to islets in culture using E1-, E3-deleted adenoviral vectors Human or mouse islets were washed twice in serum-free RPMI 1640 (Gibco-BRL) supplemented with a 1% penicillin/streptomycin solution (Gibco-BRL) prior to infection. In all, 50-400 islets were routinely infected with Ad-TNFR-Ig at a PFU of 1 Â 10 4 -1 Â 10 6 in a minimal volume of serum-free RPMI 1640 for 1-2 h at 371C. Following the infection, the islets were washed three times in medium containing 10% heat-inactivated fetal calf serum (Gibco-BRL). Islets were then incubated at 371C in medium with serum for 2 days, after which all the assays or transplants were carried out. All the functional assays described below were performed on at least three different occasions unless otherwise indicated.
Detection of TNFR-Ig expression and secretion
Secreted TNFR-Ig protein was detected in the culture supernatants 2 days following infection using a commercially available ELISA kit (R&D Systems, Indianapolis, IN, USA). This also coincided with the day of cytokine treatment in the designated cultures. Furthermore, to confirm protein expression, human islets were transduced with 5 or 100 MOI Ad-TNFR-Ig. After 2 days, the islets were lysed and the lysates processed for Western blotting. Islet lysate was loaded with Laemmli buffer (containing 2-mercaptoethanol) on a 12.5% precast polyacrylamide gradient gel (Cambrex, Rockland, ME, USA), after being heated at 1001C for 5 min. The gel was run for approximately 1.5 h at 150 V in Tris/Glycine/SDS running buffer (BioRad, Hercules, CA, USA). The gel was transferred onto a Hybond-P PVDF membrane (Amersham, Piscataway, NJ, USA) in Tris/Glycine/10% methanol transfer buffer. The membrane was subsequently blocked for 1 h in 5% milk/PBS/0.05% Tween 20. Following washing in PBST, the membrane was incubated with an antibody specific for the extracellular ligand-binding domain of the human type 1 TNF receptor (clone BAF225, R&D Systems, Indianapolis, IN, USA) at 0.2 mg/ml in 5% BSA. The membrane was washed for 20 min with PBST at room temperature and then incubated with a rabbit anti-goat secondary antibody (Jackson Immunoresearch, West Grove, PA, USA) at a dilution of 1:10 000 in 5% milk/PBST. Following a wash in PBST, the immunoreactive protein was visualized using the ECL kit (Amersham, Piscataway, NJ, USA) on a Kodak Biomax film.
Evaluation of b-cell function following cytokine treatment
To assess the effects of TNFa with or without IL-1b on the b-cell function of transduced and control islets, we performed 60-min dynamic glucose perifusion assays, alternating low-high glucose levels in perfusion chambers.
IL-1b (R&D Systems, Indianapolis, IN, USA) for a period between 18 and 24 h. The cytokine-containing medium was removed and the islets were washed twice in perifusion medium (Krebs-Ringer buffer, pH 7.4, without glucose), followed by perifusion in 5-20 mM glucose. At the indicated time points, perifusate aliquots were removed for the determination of insulin secretion by a commercially available ELISA kit (Mercodia Inc, Metuchen, NJ, USA), which specifically recognizes processed human insulin. The value for the insulin level detected at each time point was corrected for DNA content in the corresponding islet clusters from the perifusion using the CyQuant reagent system (Molecular Probes, Eugene, OR, USA).
Assessment of apoptosis activation in vitro
Uninfected islets, Ad-eGFP and Ad-TNFR-Ig-transduced islets were treated with cytokines as described above. At the end of the incubation, single cells were obtained from intact islets using a trypsin-free cell-dissociation buffer (InVitrogen-Gibco Life Sciences, Gaithersburg, MD, USA). Single cells were processed for Annexin V levels using a commercially available kit (BD Biosciences, San Diego, CA, USA). Single cells were further treated with propidium iodide and analyzed by FACS (FACSVantage, BD Instruments, San Diego, CA, USA). Annexin V + / propidium iodide-negative cells were assigned to be early apoptotic cells, while double-positive cells were assigned as late-apoptotic/dead cells.
Statistics
Statistics were performed using GraphPad Prism version 4.0. P-values o0.05 by ANOVA or two-tailed Student's t-test were taken to indicate statistically significant differences among treatment groups. Additionally, Kaplan-Meier log-rank P-values o0.05 were deemed statistically significant in survival analysis of transplant recipients.
